Clinical Trial Update: A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ensartinib as neoadjuvant therapy for patients with ALK-positive resectable non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ensartinib (Ensartinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN